Lundquist Investigator Loren Miller, MD, MPH, will be honored with a 2024 Top Ten Clinical Research Achievement Award by the Clinical Research Forum (CR Forum) at a Las Vegas, NV ceremony, on April 2, 2024. Dr. Miller is an Investigator at TLI, Chief of Infectious Diseases at Harbor-UCLA Medical Center, and a Professor of Medicine at the David Geffen School of Medicine at UCLA.
The Top 10 Clinical Research Achievement Awards honor groundbreaking achievements in clinical research nationwide. The award recognizes the Protect Trial, a clinical trial jointly led by Dr. Miller and senior investigator Susan Huang, MD, MPH, Chancellor’s Professor at the University of California, Irvine. The Protect Trial involved nearly 14,000 residents in 28 California nursing homes in Los Angeles and Orange counties.
This initiative seeks to improve emergency medical services in L.A. County by drastically reducing post-motor vehicle crash deaths through a new protocol mobile application
The California Office of Traffic Safety through the National Highway Traffic Safety Administration has awarded The Lundquist Institute, Los Angeles County Emergency Medical Services, and the Harbor-UCLA Department of Emergency Medicine a $1 Million grant to facilitate the development and implementation of an innovative mobile application aimed at enhancing prehospital trauma care.
In the Pediatrics article, “The Management of Children and Youth Pediatric Mental and Behavioral Health Emergencies,” Dr. Saidinejad and his co-authors note that “mental and behavioral health (MBH) conditions affect as many as 1 in 5 children younger than 18 in the United States each year.” Given the increasing need for MBH treatment for children and youth, emergency departments in hospitals are now a critical access point and safety net as the wait time for child psychiatrists can be more than 40 days. Dr.
AHRQ-funded Study Finds “Universal Decolonization” Lowers Hospital Transfers Due to Infection from Methicillin-Resistant Staphylococcus aureus (MRSA)
Nursing homes that use a chlorhexidine bathing routine to clean the skin, and an over-the-counter antiseptic to clean the nose, prevent serious infections and reduce the amount of antibiotic-resistant organisms in the nursing home setting, according to the findings of researchers at Harbor-UCLA Medical Center, the University of California, Irvine, and the Centers for Disease Control and Prevention (CDC). The findings were published on October 10, 2023, in the New England Journal of Medicine.
Leaders from The Lundquist Institute (TLI) participated in Advocacy Day on Sept. 12, 2023, at the nation's capital as part of the Association of Independent Research Institutes (AIRI) annual conference in Washington, D.C. TLI leaders met with congressional staff regarding the importance of federal science research funding. (Pictured from left at the Capitol building: John Munz, Vice President for Human Resources; Kerstin Lynam, Chief Operating Officer; Mike Jones, Chief Financial Officer; Dr. David Meyer, President & CEO; Jody Spillane, Sr.
The Lundquist Institute (TLI) Investigator, Harry Rossiter, PhD, has been awarded a five-year R01 grant totaling $3.8 Million from the National Institutes of Health’s National Heart Lung and Blood Institute (NIH/NHLBI). The R01 is the most prestigious and competitive NIH grant (only 10% are funded) awarded to biomedical researchers.
Dr. Rossiter’s research team at TLI has developed the next generation of the cardiopulmonary exercise test; the standard clinical test to investigate exercise intolerance. The new test, termed muscle-CPET or “mCPET,” will for the first time, integrate direct assessments of neuromuscular performance, with the existing technology that assesses the function of the cardiovascular and pulmonary systems under the stress of exercise.
TRDRP Research grant and JDRF multi-PI grant will help to establish the basis of diabetes and provides new therapeutics
Lundquist Institute investigator Eiji Yoshihara, Ph.D., has received two grants for the research related to type 1 and type 2 diabetes. A three-year $1.45 Million research award from The Tobacco-Related Disease Research Program (TRDRP) and a three-year total $300,000/institution, multi-institutional/multi-PI research grant from the JDRF (formerly known as Juvenile Diabetes Research Foundation). For the TRDRP research, Dr. Yoshihara’s lab and research collaborator Dr.
The research will apply state-of-the-art science to address antibiotic-resistant bloodstream infections caused by Staphylococcus aureus (MRSA) and Candida albicans
The Lundquist Institute (TLI) at Harbor-UCLA Medical Center has announced that TLI Principal Investigator, Michael Yeaman, PhD, has been awarded a grant totaling $11.5M from the National Institute of Allergy and Infectious Diseases (NIAID), Department of Health & Human Services. Along with his role at TLI, Dr. Yeaman is Professor of Medicine at UCLA, and Chief, Division of Molecular Medicine at Harbor-UCLA Medical Center.
The gift will facilitate an FDA-approved multi-site clinical trial under the co-direction of Lundquist Investigators, Dr. Charles S. Grob and Dr. Anthony P. Bossis
The Joe & Sandy Samberg Foundation has made a gift of $300,000 to The Lundquist Institute (TLI) to study the use of psilocybin in alleviating demoralization and the psychological distress associated with life-threatening illness in palliative care. The gift will support the work of Charles Grob, MD, an investigator at TLI and professor at the David Geffen School of Medicine at UCLA and Anthony P. Bossis, PhD, an investigator at TLI. The gift will facilitate an FDA-approved multi-site clinical trial.
The NIH Award will Support Dr. Rehan’s and Advent’s Research to Develop and Position Its Novel Aerosolized Vitamin A Formulation for Commercialization to Prevent BPD
The Lundquist Institute and Advent Therapeutics have announced a landmark collaboration that has resulted in a significant $3 million Small Business Innovation Research (SBIR) Phase IIB grant from the National Institutes of Health (NIH). The funding will directly support the groundbreaking work of Dr. Rehan Virender, which focuses on developing a first-of-its-kind aerosolized vitamin A formulation. This innovative treatment aims to counteract Bronchopulmonary Dysplasia (BPD), a life-threatening condition affecting premature infants, with an eye towards commercialization by 2025.